Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Palvella Therapeutics, Inc. (PVLA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$156.85-3.35%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for PVLA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Achieve first FDA approval by first half of 2027 | The company targets FDA approval by early 2027. | Improving | FDA approval not granted by 2027-06-30 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, loss-making biotech with a rare-disease pipeline, not an established earnings compounder. Its long-term thesis remains on watch: regulatory and pipeline work is advancing, but recent results are weak and risk is elevated.
PVLA is described as cheap versus peers, though the valuation model has low confidence. The priced-in assessment is justified rather than fragile: weak execution quality is reflected, but the evidence does not show that the full combination of high valuation, weak execution, and turbulence is priced in.
Near term, consecutive earnings misses and elevated risk of another miss make results uncertain. Over the multi-year view, the first rolling QTORIN NDA module and reported trial progress support pipeline advancement, while higher operating losses and R&D spending show that financial discipline and launch readiness remain unproven.
The thesis hinges on completing the NDA submission and preparing for a potential U.S. launch in the first half of 2027, while controlling losses. A guidance cut or further weakening in jobs data could add pressure; continued earnings strength and higher guidance from sector bellwethers could support the broader healthcare backdrop.
Over the next one to three years, PVLA’s case rests on regulatory execution and commercial preparation catching up with its spending, with near-term earnings risk still elevated. The evidence supports a watch state, not a settled long-term thesis. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Management is focused on financial stability despite current losses. |
| Under Pressure |
| Operating loss or cash flow worse than -$14.9M or -$10.9M respectively in 2026-Q1 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
NDA submission on track for second half of 2026 | Palvella aims to submit its NDA in the second half of 2026. | Improving | NDA submission delayed beyond 2026-12-31 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-6.54 → $-8.29 · observed estimates
$0.03B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-6.54 | $28,699,963 | 9 / 10 |
| 2026-07-25 | $-6.54 | $28,699,963 | 9 / 10 |
| 2026-07-26 | $-6.54 | $28,699,963 | 9 / 10 |
| 2026-07-27 | $-6.54 | $28,699,963 | 9 / 10 |
| 2026-07-28 | $-6.54 | $28,699,963 | 9 / 10 |
| 2026-07-29 | $-6.54 | $28,699,963 | 9 / 10 |
| 2026-07-30 | $-6.38 | $30,550,150 | 10 / 13 |
| 2026-07-31 | $-6.54 | $28,699,963 | 9 / 10 |
| 2026-08-01 | $-6.54 | $28,699,963 | 9 / 10 |
| 2026-08-02 | $-6.38 | $30,550,150 | 10 / 13 |
| 2026-08-03 | $-6.54 | $28,699,963 | 9 / 10 |
| 2026-08-04 | $-6.54 | $28,699,963 | 9 / 10 |
| 2026-08-05 | $-6.99 | $29,027,000 | 10 / 13 |
| 2026-08-06 | $-6.54 | $28,699,963 | 9 / 10 |
| 2026-08-07 | $-7.81 | $27,363,837 | 9 / 10 |
| 2026-08-08 | $-7.40 | $29,025,380 | 10 / 13 |
| 2026-08-09 | $-7.40 | $29,025,380 | 10 / 13 |
| 2026-08-10 | $-7.40 | $29,025,380 | 10 / 13 |
| 2026-08-12 | $-7.81 | $27,363,837 | 9 / 10 |
| 2026-08-13 | $-7.81 | $27,363,837 | 9 / 10 |
| 2026-08-14 | $-7.81 | $27,363,837 | 9 / 10 |
| 2026-08-15 | $-7.81 | $27,363,837 | 9 / 10 |
| 2026-08-16 | $-7.81 | $27,363,837 | 9 / 10 |
| 2026-08-17 | $-7.81 | $27,363,837 | 9 / 10 |
| 2026-08-18 | $-7.81 | $27,363,837 | 9 / 10 |
| 2026-08-19 | $-7.81 | $27,363,837 | 9 / 10 |
| 2026-08-20 | $-7.81 | $27,363,837 | 9 / 10 |
| 2026-08-21 | $-7.81 | $27,363,837 | 9 / 10 |
| 2026-08-22 | $-7.81 | $27,363,837 | 9 / 10 |
| 2026-08-23 | $-7.81 | $27,363,837 | 9 / 10 |
| 2026-08-24 | $-7.81 | $27,363,837 | 9 / 10 |
| 2026-08-25 | $-7.81 | $27,363,837 | 9 / 10 |
| 2026-08-26 | $-7.81 | $27,363,837 | 9 / 10 |
| 2026-08-27 | $-7.81 | $27,363,837 | 9 / 10 |
| 2026-08-28 | $-7.81 | $27,363,837 | 9 / 10 |
| 2026-08-29 | $-8.10 | $28,034,760 | 9 / 10 |
| 2026-08-30 | $-8.10 | $28,034,760 | 9 / 10 |
| 2026-08-31 | $-8.10 | $28,034,760 | 9 / 10 |
| 2026-09-01 | $-8.10 | $28,034,760 | 9 / 10 |
| 2026-09-02 | $-8.10 | $28,034,760 | 9 / 10 |
| 2026-09-03 | $-8.10 | $28,034,760 | 9 / 10 |
| 2026-09-04 | $-8.10 | $28,034,760 | 9 / 10 |
| 2026-09-05 | $-8.31 | $27,922,171 | 9 / 10 |
| 2026-09-06 | $-8.31 | $27,922,171 | 9 / 10 |
| 2026-09-07 | $-8.31 | $27,922,171 | 9 / 10 |
| 2026-09-08 | $-8.31 | $27,922,171 | 9 / 10 |
| 2026-09-09 | $-8.31 | $27,922,171 | 9 / 10 |
| 2026-09-10 | $-8.31 | $27,922,171 | 9 / 10 |
| 2026-09-11 | $-8.31 | $27,922,171 | 9 / 10 |
| 2026-09-12 | $-8.31 | $27,893,600 | 9 / 10 |
| 2026-09-13 | $-8.31 | $27,893,600 | 9 / 10 |
| 2026-09-14 | $-8.31 | $27,893,600 | 9 / 10 |
| 2026-09-15 | $-8.31 | $27,893,600 | 9 / 10 |
| 2026-09-16 | $-8.31 | $27,893,600 | 9 / 10 |
| 2026-09-17 | $-8.31 | $27,893,600 | 9 / 10 |
| 2026-09-18 | $-8.31 | $27,893,600 | 9 / 10 |
| 2026-09-19 | $-8.31 | $27,893,600 | 9 / 10 |
| 2026-09-20 | $-8.31 | $27,893,600 | 9 / 10 |
| 2026-09-21 | $-8.31 | $27,893,600 | 9 / 10 |
| 2026-09-22 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-09-23 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-09-24 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-09-25 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-09-26 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-09-27 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-09-28 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-09-29 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-09-30 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-10-01 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-10-02 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-10-03 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-10-04 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-10-05 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-10-06 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-10-07 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-10-08 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-10-09 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-10-10 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-10-11 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-10-12 | $-7.98 | $27,187,360 | 9 / 10 |
| 2026-10-13 | $-8.39 | $25,469,560 | 9 / 10 |
| 2026-10-14 | $-8.39 | $25,469,560 | 9 / 10 |
| 2026-10-15 | $-8.39 | $25,469,560 | 9 / 10 |
| 2026-10-16 | $-8.39 | $25,469,560 | 9 / 10 |
| 2026-10-17 | $-8.39 | $25,469,560 | 9 / 10 |
| 2026-10-18 | $-8.28 | $24,474,106 | 10 / 11 |
| 2026-10-19 | $-8.28 | $24,474,106 | 10 / 11 |
| 2026-10-20 | $-8.28 | $24,474,106 | 10 / 11 |
| 2026-10-21 | $-8.28 | $24,470,919 | 10 / 11 |
| 2026-10-22 | $-8.34 | $23,583,419 | 10 / 11 |
| 2026-10-23 | $-8.34 | $23,582,425 | 10 / 11 |
| 2026-10-24 | $-8.34 | $23,582,425 | 10 / 11 |
| 2026-10-25 | $-8.34 | $23,582,425 | 10 / 11 |
| 2026-10-26 | $-8.34 | $23,582,425 | 10 / 11 |
| 2026-10-27 | $-8.34 | $23,582,425 | 10 / 11 |
| 2026-10-28 | $-8.34 | $23,582,425 | 10 / 11 |
| 2026-10-29 | $-8.29 | $23,568,275 | 10 / 11 |
| 2026-10-30 | $-8.29 | $23,568,275 | 10 / 11 |
| 2026-10-31 | $-8.29 | $23,568,275 | 10 / 11 |
| 2026-11-01 | $-8.29 | $23,568,275 | 10 / 11 |
| 2026-11-02 | $-8.29 | $23,568,275 | 10 / 11 |
| 2026-11-03 | $-8.29 | $23,568,275 | 10 / 11 |
| 2026-11-04 | $-8.29 | $23,568,275 | 10 / 11 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 16 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 2 recorded
0 raises · 1 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.